Press Releases on September 17, 2018 - EIN Presswire - Press Release Distribution Service

Published on September 17, 2018 - 12:30 GMT

Menlo Therapeutics Begins European Prurigo Nodularis Phase 3 Trial and Presents Additional Data from PN Phase 2 Trial at EADV

REDWOOD CITY, Calif., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated with various conditions and for …

Distribution channels: Technology ...

Published on September 17, 2018 - 12:30 GMT

NetworkNewsAudio Announces Audio Press Release (APR) on Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTC: STLHF) Aiming to ...

NEW YORK, Sept. 17, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsAudio announces the Audio Press Release (APR) titled “New Technologies May Turn Arkansas into a Lithium Superpower,” featuring Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTC: …

Distribution channels: Media, Advertising & PR ...

Published on September 17, 2018 - 12:30 GMT

Argentum 47 Inc.’s CEO, Peter Smith, Discusses its Recent Acquisition and Future Acquisitions with Everett Jolly on Uptick ...

PHOENIX, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Argentum 47, Inc. (OTC: ARGQ), (the “Company”) announced CEO Peter Smith’s interview on Uptick Newswire’s “Stock Day” Podcast. Everett Jolly invited, Peter Smith, CEO of Argentum 47, Inc., to the “Stock Day” …

Distribution channels:

Published on September 17, 2018 - 12:30 GMT

Capstone Continues to Expand CHP Business with Order for Newly Constructed Educational Campus in Arizona

VAN NUYS, Calif., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Capstone Turbine Corporation (www.capstoneturbine.com) (Nasdaq: CPST), the world’s leading clean technology manufacturer of microturbine energy systems, announced today it continues to expand into the …

Distribution channels: Electronics Industry ...

Published on September 17, 2018 - 12:30 GMT

Interpace Diagnostics Supports Research Efforts of Pancreatic and Thyroid Cancer Patient Advocacy Groups

Interpace Employees Participate in Local Events in Support of Lustgarten Foundation for Pancreatic Cancer Research, Thyroid, Head and Neck Cancer Foundation, and Pancreatic Cancer Action Network PARSIPPANY, NJ, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Interpace …

Distribution channels:

Published on September 17, 2018 - 12:30 GMT

Amyris Provides Update on Leland, NC Production Facility

EMERYVILLE, Calif., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, has monitored …

Distribution channels: Chemical Industry ...

Published on September 17, 2018 - 12:30 GMT

New Independent Data Further Demonstrates Clinical Utility of Daxor Corporation’s Blood Volume Analyzer (BVA-100) Over Surrogate ...

NEW YORK, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the presentation of two Mayo …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on September 17, 2018 - 12:30 GMT

Huazhu Group Limited Provides Updates on Investigation Status of the Alleged Information Leak

SHANGHAI, China, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Huazhu Group Limited (NASDAQ:HTHT) (“Huazhu” or the “Company”), a leading and fast-growing multi-brand hotel group in China, today provided updates on the investigation status of the alleged information …

Distribution channels: Travel & Tourism Industry ...

Published on September 17, 2018 - 12:30 GMT

Amalgamation of Automotive and Technology has Introduced Gainful Avenues for Automotive Mobile Accessories Market, reveals Fact.MR

Rockville, MD, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Incorporation of technological up-to-date mobile accessories in automobiles is slated to be heavily influenced by spate of unstoppable innovation in the automotive industry. The call for seamless cross- …

Distribution channels: Banking, Finance & Investment Industry, Technology ...

Published on September 17, 2018 - 12:30 GMT

Human medicines European public assessment report (EPAR): Tevagrastim, filgrastim, Neutropenia;Hematopoietic Stem Cell ...

Tevagrastim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:30 GMT

Human medicines European public assessment report (EPAR): Tevagrastim, filgrastim, Neutropenia;Hematopoietic Stem Cell ...

Tevagrastim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:30 GMT

Human medicines European public assessment report (EPAR): Hexyon, diphtheria, tetanus, pertussis (acellular, component), hepatitis ...

Hexyon has been studied in several countries worldwide in 12 main studies involving over 3,400 children between six weeks and two years of age who were given three doses of the vaccine during their first six months of life according to different local …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:30 GMT

Human medicines European public assessment report (EPAR): Hexyon, diphtheria, tetanus, pertussis (acellular, component), hepatitis ...

Hexyon has been studied in several countries worldwide in 12 main studies involving over 3,400 children between six weeks and two years of age who were given three doses of the vaccine during their first six months of life according to different local …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:30 GMT

Human medicines European public assessment report (EPAR): Multaq, dronedarone, Atrial Fibrillation, Date of authorisation: 25/11/...

There were six main studies of Multaq in adults who had had atrial fibrillation. The first three studies, involving, 1,411 patients, found that Multaq was more effective than placebo (a dummy treatment) at preventing atrial fibrillation. The main measure …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:30 GMT

Human medicines European public assessment report (EPAR): Multaq, dronedarone, Atrial Fibrillation, Date of authorisation: 25/11/...

There were six main studies of Multaq in adults who had had atrial fibrillation. The first three studies, involving, 1,411 patients, found that Multaq was more effective than placebo (a dummy treatment) at preventing atrial fibrillation. The main measure …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:30 GMT

Human medicines European public assessment report (EPAR): Flebogamma DIF (previously Flebogammadif), human normal immunoglobulin, ...

Replacement therapy in adults, children and adolescents (0-18 years) in: primary immunodeficiency syndromes with impaired antibody production; hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:30 GMT

Human medicines European public assessment report (EPAR): Flebogamma DIF (previously Flebogammadif), human normal immunoglobulin, ...

Replacement therapy in adults, children and adolescents (0-18 years) in: primary immunodeficiency syndromes with impaired antibody production; hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:29 GMT

Human medicines European public assessment report (EPAR): Lopinavir/Ritonavir Mylan, lopinavir,ritonavir, HIV Infections, Date of ...

Lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years. The choice of lopinavir/ …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:29 GMT

Human medicines European public assessment report (EPAR): Lopinavir/Ritonavir Mylan, lopinavir,ritonavir, HIV Infections, Date of ...

Lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years. The choice of lopinavir/ritonavir to …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:29 GMT

Human medicines European public assessment report (EPAR): Invokana, canagliflozin, Diabetes Mellitus, Type 2, Date of ...

Invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise: as monotherapy when metformin is considered inappropriate due to intolerance or contraindications in addition to …

Distribution channels: Healthcare & Pharmaceuticals Industry